607371-03-9

Usage

Uses

Used in Pharmaceutical Research and Development:
5-Bromo-N4-ethylpyridine-3,4-diamine is utilized as a chemical intermediate for the synthesis of pharmaceutical compounds due to its unique structural features and potential biological activities.
Used in Cancer Treatment Research:
In the field of oncology, 5-bromo-N4-ethylpyridine-3,4-diamine is studied as a potential therapeutic agent for the treatment of cancer, given its capacity to inhibit certain enzymes and receptors that may play a role in tumor growth and progression.
Used in Medicinal Chemistry:
5-Bromo-N4-ethylpyridine-3,4-diamine is employed as a key building block in the design and synthesis of new molecules with potential medicinal properties, contributing to the discovery of novel drugs and therapeutic agents.
Used in Organic Synthesis:
5-bromo-N4-ethylpyridine-3,4-diamine is also used as a reagent in organic synthesis, facilitating the creation of a variety of organic molecules that may have applications in different industries, including pharmaceuticals, materials science, and agrochemicals.

Upstream product

• 607371-01-7 ethyl-(3-bromo-5-nitropyridin-4-yl)amine 
• 562825-95-0 ethyl-(3-nitropyridin-4-yl)amine 

Downstream Products

• 842143-97-9 (7-bromo-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)acetonitrile 
• 607370-99-0 4-(7-bromo-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)oxadiazolidin-3-ylamine 

Relevant academic research and scientific papers

Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3- piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase

Overexpression of AKT has an antiapoptotic effect in many cell types, and expression of dominant negative AKT blocks the ability of a variety of growth factors to promote survival. Therefore, inhibitors of AKT kinase activity might be useful as monotherapy for the treatment of tumors with activated AKT. Herein, we describe our lead optimization studies culminating in the discovery of compound 3g (GSK690693). Compound 3g is a novel ATP competitive, pan-AKT kinase inhibitor with IC50 values of 2, 13, and 9 nM against AKT1, 2, and 3, respectively. An X-ray cocrystal structure was solved with 3g and the kinase domain of AKT2, confirming that 3g bound in the ATP binding pocket. Compound 3g potently inhibits intracellular AKT activity as measured by the inhibition of the phosphorylation levels of GSK3β. Intraperitoneal administration of 3g in immunocompromised mice results in the inhibition of GSK3β phosphorylation and tumor growth in human breast carcinoma (BT474) xenografts.

INHIBITORS OF Akt ACTIVITY

Invented are novel 1 H-imidazo[4,5-c]pyridin-2-yI compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.

CANCER TREATMENT METHOD

The present invention relates to a method of treating cancer in a mammal and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering an erb family inhibitor and a PI3K and/or Akt inhibitor to a mammal suffering from a cancer.

(1H-Imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: Further optimisation as highly potent and selective MSK-1-inhibitors

The novel imidazo[4,5-c]pyridine 1,2,5-oxadiazol-3-yl template affords an excellent start point for identification of inhibitors of a number of protein kinases. Here we report on its optimisation for mitogen and stress-activated protein kinase-1 (MSK-1) inhibitory activity, and selectivity over other kinases.